BACKGROUND: Neuropsychological examinations have shown an elevated risk for cognitive impairment 2 years after therapy in breast cancer patients randomized to receive adjuvant high-dose cyclophosphamide, thiotepa, carboplatin (CTC) chemotherapy compared with a non-treated control group of stage I breast cancer patients. Patients randomized to receive standard-dose fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy showed no elevated risk compared with controls. However, breast cancer patients treated with conventional cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy showed a higher risk of cognitive impairment. The present study was designed to obtain a greater insight into these long-term neuropsychological sequelae following chemotherapy and their course in time. PATIENTS AND METHODS: At 4 years post-therapy, 22 of the original 34 CTC patients, 23 of 36 FEC patients, 31 of 39 CMF patients and 27 of 34 control patients were re-examined with neuropsychological tests. RESULTS:Improvement in performance was observed in all chemotherapy groups, whereas in the control group there was a slight deterioration in test results. A differential attrition was observed among the groups, with a relatively high percentage of initially cognitively impaired patients from the CTC group dropping out due to factors related to disease progression. CONCLUSIONS: The results suggest that cognitive dysfunction following adjuvant chemotherapy in breast cancer patients may be transient. Additional studies are needed to investigate the differential attrition of patients with cognitive impairment.
RCT Entities:
BACKGROUND: Neuropsychological examinations have shown an elevated risk for cognitive impairment 2 years after therapy in breast cancerpatients randomized to receive adjuvant high-dose cyclophosphamide, thiotepa, carboplatin (CTC) chemotherapy compared with a non-treated control group of stage I breast cancerpatients. Patients randomized to receive standard-dose fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy showed no elevated risk compared with controls. However, breast cancerpatients treated with conventional cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy showed a higher risk of cognitive impairment. The present study was designed to obtain a greater insight into these long-term neuropsychological sequelae following chemotherapy and their course in time. PATIENTS AND METHODS: At 4 years post-therapy, 22 of the original 34 CTC patients, 23 of 36 FEC patients, 31 of 39 CMFpatients and 27 of 34 control patients were re-examined with neuropsychological tests. RESULTS: Improvement in performance was observed in all chemotherapy groups, whereas in the control group there was a slight deterioration in test results. A differential attrition was observed among the groups, with a relatively high percentage of initially cognitively impairedpatients from the CTC group dropping out due to factors related to disease progression. CONCLUSIONS: The results suggest that cognitive dysfunction following adjuvant chemotherapy in breast cancerpatients may be transient. Additional studies are needed to investigate the differential attrition of patients with cognitive impairment.
Authors: Kristin M Phillips; Heather S Jim; Brent J Small; Christine Laronga; Michael A Andrykowski; Paul B Jacobsen Journal: Cancer Date: 2011-12-12 Impact factor: 6.860
Authors: Brenna C McDonald; Susan K Conroy; Dori J Smith; John D West; Andrew J Saykin Journal: Brain Behav Immun Date: 2012-05-18 Impact factor: 7.217
Authors: Patricia A Ganz; Lorna Kwan; Steven A Castellon; Amy Oppenheim; Julienne E Bower; Daniel H S Silverman; Steve W Cole; Michael R Irwin; Sonia Ancoli-Israel; Thomas R Belin Journal: J Natl Cancer Inst Date: 2013-04-19 Impact factor: 13.506
Authors: Karin Olson; Joanne Hewit; Linda G Slater; Thane Chambers; Deborah Hicks; Anna Farmer; Kathryn Grattan; Shawn Steggles; Bryan Kolb Journal: Support Care Cancer Date: 2016-04-11 Impact factor: 3.603